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McAdam-Marx C, Brixner D, Oberg B
The University of Utah College of Pharmacy, Salt Lake City, UT, USA
The lag between product launch and prescribing impacts
research timing. This will describe methods applied to a popula-
tion treated with a new antidiabetic agent, exenatide, to project
patient counts for 6 months and 12 months real-world outcomes
analyses. Patients prescribed exenatide via the General Electric
Electronic Medical Record (EMR) database by March 31, 2007
were identiﬁed. The proportions of patients remaining active 6
months and 12 months on March 31, 2007 and with baseline
and follow-up hemoglobin A1C values were identiﬁed. Starts for
2Q07 were estimated based on 4Q06 to 1Q07 growth, and the
number of patients who would have started exenatide at least 6
months or 12 months before December 31, 2007 was projected.
Rates and portions with A1C values were applied to these counts
to predict how many would be active at least 6 months and 12
months on December 31, 2007 and have outcomes data.
Exenatide was prescribed for 8372 patients through March 31,
2007. A total of 5392 and 2240 started exenatide at least 6
months or 12 months prior to March 31, 2007. A total of 2853
(52.9%) had 6 months and 1152 (51.4%) had 12 months activ-
ity. Of these 1721 (60.3%) and 789 (68.5%) had baseline and
follow-up A1C readings. The rate for 1Q07 was 20%; thus the
estimated number prescribed exenatide by the end of 2Q07 was
10,043. Thus, 10,043 and 6946 would be prescribed exenatide at
least 6 months and 12 months before December 31, 2007. Of
these, 3207 and 2447 would be active and have baseline and
follow-up A1C values. Estimates based on prescribing growth
and patient retention was used to estimate patient counts for
outcomes analysis. This facilitates research and planning for
research on a new product. A validation of estimates will be
conducted and reported when available.
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COMPARISON OF CLINICAL EFFECTIVENESS AND SAFETY
OF GLULISINEVERSUS INSULIN LISPRO,ASPART AND
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2 DIABETES
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OBJECTIVE: The aim of this analysis was to compare clinical
effectiveness of insulin glulisine versus insulin lispro, aspart and
regular human insulin in patients with type 1 and 2 diabetes.
METHODS: The clinical effectiveness was analyzed according to
guidelines of Cochrane Collaboration and HTA Agency in
Poland (AOTM). The comparison of insulin glulisine with com-
parators was performed as direct comparisons. RESULTS:
Patients with type 1 diabetes: There was no statistically signiﬁ-
cant difference between insulin glulisine and insulin lispro, aspart
and regular human insulin in change in mean HbA1c from base-
line. Also there was no statistically signiﬁcant difference between
groups in number of patients with hypoglycemia (overall, noc-
turnal and severe). The comparison of safety parameters for
insulin glulisine versus insulin lispro, aspart and regular human
insulin didn’t show signiﬁcant differences between analyzed
groups. Patient with type 2 diabetes: Meta-analysis of two clini-
cal trials showed no statistically signiﬁcant difference between
insulin glulisine and regular human insulin in change of mean
HbA1c. However in one study there was statistically signiﬁcant
difference in favour of insulin glulisine compared to regular
human insulin in change of HbA1c -0.11%(95% CI: -0.21;
-0.008) after 26 week of follow up. There was relevant difference
between the two groups in favour of insulin glulisine in reporting
of nocturnal hypoglycemia OR: 0.73 (95% CI: 0.57; 0.94). Fre-
quency of adverse events was comparable between groups.
CONCLUSION: Insulin glulisine has efﬁcacy comparable to
insulin aspart, lispro and regular human insulin in patients with
type 1 diabetes. Insulin glulisine, in comparison with regular
human insulin is more effective in treatment of patients with type
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Livengood K
University of Southern California, Los Angeles, CA, USA
OBJECTIVE: The purpose of this analysis was to determine if
high-risk cardiovascular patients with concomitant diabetes and
a pre-treatment A1c measurement greater than 9% experienced
better outcomes with insulin containing anti-diabetic medication
regimens than similar patients not taking insulin. METHODS:
High-risk cardiovascular patients with concomitant diabetes and
a pre-treatment A1c measurement of greater than 9% from a
large western United States integrated health care system were
evaluated for an A1c measurement at least three months prior to
treatment initiation and a follow-up measurement at least three
months following initiation. In the case of patients taking insulin,
the three month follow-up period started with the initiation of
insulin. Change in A1c resulting from medication treatment was
evaluated using a two-step endogenous treatment regression
model, with insulin as the endogenous treatment variable. Exog-
enous independent variables included hypertension diagnosis,
hyperlipidemia diagnosis, age, gender, and distance from treat-
ment goal (A1c less than 7%) at baseline. Standard errors for
beta coefﬁcients were computed using HCCM3. RESULTS: Of
11,181 diabetic patients, 707 (314 on insulin) patients met the
inclusion criteria. Although both insulin and non-insulin contain-
ing treatment regimens reduced A1c from baseline to follow-up,
patients on insulin were associated with a greater reduction in
A1c than patients not on insulin. The difference in change was
2.6% and was statistically signiﬁcant (p = 0.0029). CONCLU-
SION: Use of insulin in an anti-diabetic regimen in high-risk
cardiovascular patients with concomitant diabetes and a pre-
treatment A1c greater than 9% resulted in a signiﬁcantly greater
reduction in A1c compared to patients not taking insulin.
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DEFINING HYPOGLYCEMIA AND ASSESSING ITS AFFECT ON
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Quantify the impact of hypoglycemia on outcomes of hospital-
ized diabetic patients and determine how variations in the deﬁ-
nition of hypoglycemia affect outcomes. This study used an EMR
database of inpatient and ED encounters for adults with diabetes
treated at 70 hospitals during 2000–2006. Patients presenting to
Abstracts A219
